All In Biotech

Drug Trial Radar · NCT00316264

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season

Last checked: Nov 20, 2026Latest source record: Dec 11, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

260

Actual

Start

Apr 2006

Primary completion

Feb 2007

Study completion Feb 2007

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind study in which motavizumab (MEDI-524) and palivizumab were administered sequentially to high-risk children during the same respiratory syncytial virus (RSV) season. A control group was administered only motavizumab.

Conditions

  • Respiratory Syncytial Virus Infections
  • Chronic Lung Disease and <= 24 Months of Age or
  • Premature With Gestational Age <=35 Weeks and <=6 Months of Age

Interventions

  • Motavizumab, palivizumabBiological

    Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.

  • Palivizumab, motavizumabBiological

    Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.

  • MotavizumabBiological

    Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Reporting Serious Adverse Events (SAEs)Time frame: Day 0 - Day 150
  2. Number of Subjects Reporting Adverse Events (AEs)Time frame: Day 0 - Day 150
  3. Number of Subjects With Changes in Laboratory Chemistry Values Reported as AEs.Time frame: Day 0 - Day 150

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • Department of Paediatrics and Child Health, The Canberra Hospital

    Garran, Australian Capital Territory, Australia

  • Neonatalogy John Hunter Hospital

    New Lambton Heights, New South Wales, Australia

  • Caboolture Clinical Research

    Caboolture, Queensland, Australia

  • University of Queensland, Royal Children's Hospital

    Herston, Queensland, Australia

  • Peninsula Clinical Research Centre

    Kippa-Ring, Queensland, Australia

  • Women's and Children's Hospital

    North Adelaide, South Australia, Australia

  • Respiratory Medicine Department, Royal Children's Hospital

    Parkville, Victoria, Australia

  • Hospital Clinico de la Pontificia Universidad Catolica de Chile

    Santiago, Chile

  • Hospital Clinico San Borja Arriaran

    Santiago, Chile

  • Hospital Dr Felix Bulnes Cerda

    Santiago, Chile

  • Hospital Dr. Sotero del Rio

    Santiago, Chile

  • Hospital Padre Hurtado

    Santiago, Chile

  • Hospital Clinico de la Universidad de Chile

    Independencia, Santiago Metropolitan, Chile

  • Hospital San Jose

    Independencia, Santiago Metropolitan, Chile

  • Christchurch Women's Hospital

    Christchurch, New Zealand

  • Paediatric Medicine, Dunedin Hospital

    Dunedin, New Zealand

  • Department of Paediatrics, Waikato Hospital

    Hamilton, New Zealand

  • Child Health, Palmerston North Hospital

    Palmerston North, New Zealand

  • Kidz First, Middlemore Hospital

    Otahuhu, Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.